A novel mRNA-based multiepitope vaccine candidate against Cryptosporidium hominis and Cryptosporidium parvum employing reverse-vaccinology and immunoinformatics approaches

This study developed an in-silico multiepitope novel mRNA vaccine candidate for C. hominis and C. parvum with excellent structural stability, antigenicity, receptor-binding affinity, and expected immune responses. These findings offer a novel approach due to numerous species target but with significant drawbacks like no validation beyond simulation, uncertainty of long-term immunity, protein quality, stability and safety, requiring experimental validation.